Abstract 52P
Background
We evaluated the relationship between 18F-FDG uptake and mitochondrial activity in cancer cells and investigated the prognostic implications thereof in patients with invasive ductal carcinoma of the breast (IDCB).
Methods
In total, 150 consecutive patients with IDCB who underwent preoperative 18F-FDG PET/CT followed by curative surgical resection were retrospectively enrolled. Mitochondrial activity of cancer cells was assessed based on translocase of outer mitochondrial membrane 20 (TOMM20) expression and cytochrome C oxidase (COX) activity. Pearson’s correlation analysis was used to assess the relationship between SUVmax of the primary tumour (pSUVmax) and mitochondrial activity. Clinicopathological factors, including pSUVmax, histological grade, expression of ER, PR, HER2, and TOMM20, and COX activity, were assessed for prediction of progression-free survival (PFS). The Kaplan–Meier method and Cox proportional hazards model were used for the survival analysis.
Results
Sixteen of the 150 subjects (10.7%) showed progression during the follow-up period. pSUVmax correlated significantly and positively with TOMM20 expression and COX activity. Univariate analysis revealed that pSUVmax, TOMM20 expression, COX activity, ER and PR status, and histologic grade were significantly associated with PFS. Multivariate analysis revealed a significant difference in pSUVmax (HR, 4.50; 95% CI, 1.43–14.17; P = 0.010).
Conclusions
There was a significant positive correlation between 18F-FDG uptake and mitochondrial activity of cancer cells in patients with IDCB. Increased 18F-FDG uptake and mitochondrial activity were significantly associated with a shorter PFS. Therefore, assessment of preoperative 18F-FDG uptake and post-surgical mitochondrial activity in patients with IDCB could be used as marker for prediction of PFS.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Choi Byung Wook (Daegu Catholic University Medical Center).
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
YO20 - Can "Superman" have Chronic Myelomonocytic Leukemia?
Presenter: Alexander Luchinin
Session: Poster display session
Resources:
Abstract
YO21 - Sanctuary Site Central Nervous System Relapse-Refractory DLBCL Responding to Nivolumab and Lenalidomide.
Presenter: Irappa Madabhavi
Session: Poster display session
Resources:
Abstract
YO22 - External Auditory Canal Mass: A Case Series of Squamous Cell Carcinoma
Presenter: Mel Valerie Cruz-Ordinario
Session: Poster display session
Resources:
Abstract
YO23 - Soft tissue Giant cell tumor presented as Nasopharyngeal mass: A case report
Presenter: Emmelyn Buenacosa-Nepucpan
Session: Poster display session
Resources:
Abstract
YO25 - Hyperprogression after pembrolizumab in recurrent oropharyngeal cancer and the use of nab-paclitaxel as salvage treatment- A case report.
Presenter: Izzati Rosli
Session: Poster display session
Resources:
Abstract
YO26 - Exacerbation of radiation necrosis around the radiotherapy-pretreated brain metastases site after immune checkpoint inhibitors.
Presenter: Minako Nishio
Session: Poster display session
Resources:
Abstract
YO27 - Comparative Study Of 20Gray/5Fraction And 30Gray/10 Fraction Whole Brain Radiation In Brain Metastasis
Presenter: Pradip Bhandari
Session: Poster display session
Resources:
Abstract
YO28P - The response to anaplastic lymphoma kinase (ALK) inhibitor in metastatic anaplastic thyroid carcinoma (ATC)
Presenter: Nur Faizah Ab Muin
Session: Poster display session
Resources:
Abstract
YO29 - Acute kidney injury secondary to bilateral renal artery tumor thrombosis in a case of posterior mediastinal undifferentiated sarcoma: case report
Presenter: Ritsu Ibusuki
Session: Poster display session
Resources:
Abstract
YO30 - Follicular dendritic cell sarcoma of the tonsil- a multimodality approach
Presenter: Rich Ericson King
Session: Poster display session
Resources:
Abstract